A Phase 1/2 study of bicalutamide and sunitinib in RCC

Recruiting Phase 1,Phase 2 NCT06222593

Study Description

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with Treatment-Resistant Renal Cell Carcinoma

Study Details

Registry ID:: NCT06222593
Conditions:: Carcinoma, Renal Cell
Phase:: Phase 1,Phase 2
Target Enrollment:: 28 participants
Start Date:: October 1, 2024
Age Range:: 18–999 years
Healthy Volunteers:: No

Study Locations (1 site)

UB/ Great Lakes Cancer Care
Buffalo, New YorkUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →